PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA for PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA
What was lobbied
5 issue areas, each in the filer's own words, with who lobbied on it and where.
Trade (domestic/foreign) TRD
H.R. 3803, Bipartisan Congressional Trade Priorities Act of 2014: Provisions related to trade agreements S. 1900, Bipartisan Congressional Trade Priorities Act of 2014: Trade promotion authority issues Korea Free Trade Agreement: Implementation issues related to intellectual property, market access and public health Trans-Pacific Partnership (TPP): Provisions related to intellectual property, market access and public health issues Mexico and Canada IP and market access issues Turkey Market Access Issues India innovation, IP and market access issues Transatlantic Trade and Investment Partnership (TTIP): Market access, intellectual property, regulatory and other issues Issues related to Special 301 and National Trade Estimate (NTE) submissions including intellectual property and market access issues China intellectual property and market access issues International market access and intellectual property issues Biopharmaceutical innovation policy issues Trade Promotion Authority policy issues Colombia biosimilars policy issues
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOHN J CASTELLANI | — |
| CHESTER (CHIP) DAVIS | — |
| JEFFREY FRANCER | — |
| DAVID KORN | — |
| COLLEEN MALONEY | — |
| JAMES M SPEARS | — |
| MATTHEW L SULKALA | — |
Copyright/Patent/Trademark CPT
H.R. 845, Saving High-Tech Innovators from Egregious Legal Disputes Act of 2013 (the SHIELD Act): Provisions related to patent litigation H.R. 2024, End Anonymous Patents Act: Patent owner information provisions H.R. 2582, PATENT Jobs Act: Provisions related to patent user fees H.R. 2639, Patent Litigation and Innovation Act: Patent litigation provisions H.R. 2766, STOP Act: Provisions related to business method patents H.R. 2985, Combination Drug Development Incentive Act of 2013: Provisions related to exclusivity H.R. 3116, MODDERN Cures Act of 2013: Provisions related to exclusivity H.R. 3309, Innovation Act: Provisions related to patent litigation reform H.R. 3349, Innovation Protection Act: PTO Fee Diversion H.R. 3540, Demand Letter Transparency Act: Provisions related to patent demand letters H.R. 3709, Protecting Consumer Access to Generic Drugs: Provisions related to patent settlements H.R. 4287, Independent Innovator and Repurposing Act: Provisions related to patent term restoration H.R. 4763, Trade Protection not Troll Protection Act: Patent and trade provisions H.R. 5233, Trade Secrets Protection Act of 2014: Provisions related to trade secrets H.R. 5750, Orphan Product Extensions Now Accelerating Cures and Treatments Act of 2014: Provisions related to targeted IP incentives for new indications for rare diseases or conditions S. 214, Preserve Access to Affordable Generics Act: Provisions related to patent settlements S. 504, Fair and Immediate Release of Generic Drugs Act: Provisions related to patent settlements S. 627, Medical Innovation Prize Fund Act: Medical prize provisions S. 712, Patents for Humanity Program Improvement Act of 2013: Transferability of PTO vouchers provisions S. 866, Patent Quality Improvement Act of 2013: Business methods patents provisions S. 1013, Patent Abuse Reduction Act of 2013: Patent litigation provisions S. 1612, Patent Litigation Integrity Act: Patent litigation provisions including bonding S. 1720, Patent Transparency and Improvements Act: Patent litigation provisions S. 2049, Transparency in Assertion of Patents Act: Provisions related to patent demand letters S. 2150, Independent Innovator and Repurposing Act: Provisions related to patent term restoration S. 2196, Patent Fee Integrity Act: Patent fee diversion prohibition S. 2267, Defend Trade Secrets Act of 2014: Provisions related to trade secrets S. 3004, Dormant Therapies Act of 2014: Provisions related to incentives to develop biopharmaceutical products Biopharmaceutical innovation and patent policy issues Biologics data protection issues Draft legislation on demand letters, including Targeting Rogue and Opaque Letters (TROL) Act Issues related to biopharmaceutical economic incentives and intellectual property
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOHN J CASTELLANI | — |
| CHARLES M. CLAPTON | — |
| CHESTER (CHIP) DAVIS | — |
| PETER FOTOS | — |
| SASCHA HAVERFIELD-GROSS | — |
| DAVID KORN | — |
| COLLEEN MALONEY | — |
| CARA MOON | — |
| ANNE PRITCHETT | — |
| LORI REILLY | — |
| PAMELA SMITH New | Sen. Carol Moseley-Braun: Counsel and Legislative Asst. |
| JAMES M SPEARS | — |
| SARAH AMY SPURGEON New | — |
| MATTHEW L SULKALA | — |
| KRISTIN VAN GOOR New | — |
Health Issues HCR
H.R. 3742, Antibiotic Development to Advance Patient Treatment Act: Provisions related to antibiotics and drug approval H.R. 4709, Ensuring Patient Access and Effective Drug Enforcement Act: Provisions related to the Controlled Substances Act, Drug Enforcement Agency (DEA) regulation and related issues (a reintroduced version of H.R. 4069) H.R. 4299, Improving Regulatory Transparency for New Medical Therapies Act: Provisions related to DEA scheduling H.R. 5214, To require the Secretary of Health and Human Services to provide for recommendations for the development and use of clinical data registries for the improvement of patient care H.R. 5657, Fair Access for Safe and Timely (FAST) Generics Act: Provisions related to Risk Evaluation and Mitigation Strategies (REMS) H.R. 5805, Andrea Sloan Compassionate Use Reform and Enhancement Act: Provisions related to expanded access and compassionate use S. 1723, No ObamaCare Kickbacks Act of 2013: Provisions related to application of the anti-kickback statute to qualified health plans S. 2295, Patient Safety and Generic Labeling Improvement Act: Provisions related to drug safety labeling (112th Congress) S. 2917, Adding Ebola to the FDA Priority Review Voucher Program: Provisions related to new proposed voucher program; Public Law No. 113-233 Implementation issues related to the Food and Drug Administration Safety and Innovation Act (Public Law 112-144), including user fee reauthorization and FDA reform Implementation issues related to the Drug Quality and Security Act (Public Law 113-54), including pharmacy compounding and supply chain issues Implementation issues related to the Patient Protection and Affordable Care Act (PPACA) (Public Law 111-148), including health insurance exchanges Branded Prescription Drug Fee policy issues (79 Fed. Reg. 43631 (July 28, 2014)) 21st Century Cures legislation and policy issues R&D tax credit renewal as part of H.R. 5771, Tax Increase Prevention Act of 2014 Draft legislation relating to prescription drug coverage issues Issues related to value and cost of prescription drugs Issues related to user fee reauthorization and FDA reform Patient savings program policy issues Comparative effectiveness policy issues Academic detailing policy issues General HHS, NIH, and FDA related advocacy Biopharmaceutical innovation policy issues Prescription drug abuse policy issues FDA expedited drug approval policy issues Supplemental Applications Proposing Labeling Changes for Approved Drugs and Biological Products [Docket No. FDA-2013-N-0500]: Patient labeling Issues relating to communications about prescription drugs 340B program policy issues Importation policy issues Clinical trial policy issues
| Lobbyist | Covered position, as disclosed |
|---|---|
| MAYA BERMINGHAM | — |
| RANDY BURKHOLDER | — |
| JOHN J CASTELLANI | — |
| CHARLES M. CLAPTON | — |
| CHESTER (CHIP) DAVIS | — |
| PETER FOTOS | — |
| JEFFREY FRANCER | — |
| SASCHA HAVERFIELD-GROSS | — |
| LISA JOLDERSMA | — |
| DAVID KORN | — |
| COLLEEN MALONEY | — |
| CARA MOON | — |
| ANNE PRITCHETT | — |
| LORI REILLY | — |
| JENNIFER ROMANS | — |
| NICK SHIPLEY | — |
| PAMELA SMITH New | Sen. Carol Moseley-Braun: Counsel and Legislative Asst. |
| JAMES M SPEARS | — |
| SARAH AMY SPURGEON New | — |
| MATTHEW L SULKALA | — |
| KRISTIN VAN GOOR New | — |
Medicare/Medicaid MMM
H.R. 351, Protecting Seniors Access to Medicare Act of 2013: Provisions related to the Independent Payment Advisory Board H.R. 460, Patients Access to Treatments Act: Provisions related to cost sharing in the specialty tier H.R. 928, Medicare Prescription Drug Savings and Choice Act of 2013: Provisions related to Part D issues H.R. 1024, Medication Therapy Management Empowerment Act of 2013: Provisions related to medication therapy management in Part D H.R. 1102, Medicare Prescription Drug Price Negotiation Act of 2013: Provisions related to Part D issues and non-interference H.R. 1588, Medicare Drug Savings Act of 2013: Provisions related to Part D issues H.R. 2753 Securing Care for Seniors Act: Provisions related to Value Based Insurance Design H.R. 2810, Medicare Patient Access and Quality Improvement Act: Provisions related to SGR reform H.R. 2827, To amend title XVIII of the Social Security Act to allow for fair application of the exceptions process for drugs in tiers in formularies in prescription drug plans under Medicare part D: Provisions related to Medicare Part D Drug Tier Formularies H.R. 2925, Strengthening Medicare Anti-Fraud Measures Act of 2013: Provisions related to Office of Inspector General (OIG) enforcement of fraud and abuse laws H.R. 3392, Medicare Part D Patient Safety and Drug Abuse Prevention Act of 2013: Provisions related to lock-in programs H.R. 3796, Comprehensive Care Payment Innovation Act: Provisions related to alternative payment models H.R. 3890 Better Care, Lower Cost Act: Provisions related to Part D, value-based insurance design, and chronic disease H.R. 4015, SGR Repeal and Medicare Provider Payment Modernization Act of 2014: Provisions related to sustainable growth rate (SGR) and Medicare provider payment reform H.R. 4160, Keep the Promise to Seniors Act of 2014: Provisions related to Part D issues H.R. 4302, Protecting Access to Medicare Act of 2014: Provisions related to the biopharmaceutical industry H.R. 4577, Ensuring Seniors Access to Local Pharmacies Act of 2014: Provisions related to Part D preferred pharmacy networks H.R. 5183, Value Based Insurance Design for Better Care Act of 2014: Provisions related to valued base insurance design demonstration program H.R. 5558 ACO Improvement Act: Provisions related to alternate payment models H.R. 5780, Protecting Integrity in Medicare Act of 2014: Provisions related to addressing fraud and prescription drug abuse S. 117, Medicare Prescription Drug Price Negotiation Act of 2013: Provisions related to Part D issues and non-interference S. 351, Protecting Seniors Access to Medicare Act of 2013: Provisions related to Independent Payment Advisory Board S. 408, Medicare Prescription Drug Savings and Choice Act of 2013: Provision related to Part D issues S. 557, Medication Therapy Management Empowerment Act of 2013: Provisions related to Part D and medication therapy management S. 740, Medicare Drug Savings Act of 2013: Provisions related to Part D issues Deficit reduction policy issues S. 882, Stop Trafficking of Pills (STOP) Act: Provisions related to lock-in programs (112th Congress) S. 1365, Part D Beneficiary Appeals Fairness Act: Provisions related to the specialty tier in Part D S. 1871, SGR Repeal and Medicare Beneficiary Access Act of 2013: Provisions related to reforming Medicare physician payments S. 1932, Better Care, Lower Cost Act: Provisions related to Part D, value-based insurance design, and chronic disease S. 2000, SGR Repeal and Medicare Provider Payment Modernization Act of 2014: Provisions related to SGR reform S. 2110, Medicare SGR Repeal and Beneficiary Access Improvement Act of 2014: Provisions related to SGR reform Hospital Improvements for Payment (HIP) Act of 2014: Provisions related to Medicare reform (no bill number) Medicare Prescription Drug Diversion and Abuse Prevention Act: Provisions related to diversion and abuse (no bill number) Contract Year 2015 Policy and Technical Changes to the Medicare Advantage and the Medicare Prescription Drug Benefits Programs: Provisions related to Part D Proposals to increase co-payments for Part D beneficiaries receiving the low-income subsidy Medicaid Program, Covered Outpatient Drugs rulemaking Medicare sustainable growth rate policy issues Implementation issues relating to the Physician Payment Sunshine Act, including Medicare, Medicaid, Childrens Health Insurance Programs; Transparency Reports and Reporting of Physician Ownership or Investment Interests rulemaking Issues related to better use of medicine and adherence
| Lobbyist | Covered position, as disclosed |
|---|---|
| MAYA BERMINGHAM | — |
| RANDY BURKHOLDER | — |
| JOHN J CASTELLANI | — |
| CHARLES M. CLAPTON | — |
| CHESTER (CHIP) DAVIS | — |
| LISA JOLDERSMA | — |
| COLLEEN MALONEY | — |
| CARA MOON | — |
| ANNE PRITCHETT | — |
| LORI REILLY | — |
| JENNIFER ROMANS | — |
| NICK SHIPLEY | — |
| PAMELA SMITH New | Sen. Carol Moseley-Braun: Counsel and Legislative Asst. |
| JAMES M SPEARS | — |
| SARAH AMY SPURGEON New | — |
| MATTHEW L SULKALA | — |
Budget/Appropriations BUD
H.R. 83, Making consolidated appropriations for the fiscal year ending September 30, 2015, and for other purposes: Provisions related to Food and Drug Administration (FDA) funding and oversight, 340B Drug Pricing Program, and other issues H.R. 3230, Veterans Access to Care through Choice, Accountability, and Transparency Act of 2014: Provisions related to TRICARE health care program H.R. 4486, Military Construction and Veterans Affairs and Related Agencies Appropriations Act, 2015: Provisions related to TRICARE health care program H.R. 4660, Commerce, Justice, Science, and Related Agencies Appropriations Act, 2015: Provisions related to United State Trade Representative (USTR) and Patent and Trademark Office (PTO) H.R. 4800, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2015: Provisions related to FDA funding and oversight H.R. 4870, Department of Defense Appropriations Act, 2015: Provisions related to defense health programs and bio-defense H.R. 4903, Department of Homeland Security Appropriations Act, 2015: Provisions related to Customs and Border security H.R. 5464, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2015: Provisions related to 340B program, National Institutes of Health (NIH), Independent Payment Advisory Board (IPAB), and Agency for Healthcare Research & Quality (AHQR) Preparation for the FY 2016 budget
| Lobbyist | Covered position, as disclosed |
|---|---|
| MAYA BERMINGHAM | — |
| RANDY BURKHOLDER | — |
| JOHN J CASTELLANI | — |
| CHARLES M. CLAPTON | — |
| CHESTER (CHIP) DAVIS | — |
| JEFFREY FRANCER | — |
| COLLEEN MALONEY | — |
| CARA MOON | — |
| LORI REILLY | — |
| JENNIFER ROMANS | — |
| NICK SHIPLEY | — |
| PAMELA SMITH New | Sen. Carol Moseley-Braun: Counsel and Legislative Asst. |
| SARAH AMY SPURGEON New | — |
| MATTHEW L SULKALA | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.